EL
ELMD.K
—
NYSE
Health Care Equipment & Supplies
Electromed Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
15,1 %
ROE
17,4 %
Net margin
11,8 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$39,86
Open
—
Next earnings
2026-08-09
Ex-dividend
—
TR 1Y
—
About
Electromed Inc designs and manufactures high-frequency chest wall oscillation (HFCWO) devices for respiratory care, generating revenue through the sale of medical equipment and related services in the Health Care Equipment & Supplies sector.
Business. Electromed Inc (ELMD.K) is a health care equipment and supplies company that operates within the medical device industry. The firm is headquartered in the United States and is primarily listed on the New York Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.
Classification85 %
SectorHealth Care
Industry groupHealth Care Equipment & Supplies
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
Dimensional Fund Advisors, L.P.
largest disclosed fund holder
Profitability→
17,4 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to ELMD.K. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsFY 2026 earnings (expected)2026-08-09 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Electromed Inc (ELMD.K) is a health care equipment and supplies company that operates within the medical device industry. The firm is headquartered in the United States and is primarily listed on the New York Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.
Classification85 %
SectorHealth Care
Industry groupHealth Care Equipment & Supplies
AI synthesis
GENERATEDElectromed Inc maintains a conservative capital structure characterized by zero debt, resulting in a debt-to-equity ratio of 0.0. The balance sheet reflects total assets of $53.8 million against total liabilities of $10.6 million, yielding a strong equity base of $43.2 million. Liquidity is supported by cash and equivalents of $15.3 million, which covers the total liabilities more than once. Operating cash flow stands at $11.4 million, significantly exceeding capital expenditures of $0.3 million, indicating robust internal cash generation without reliance on external financing.
Profitability metrics demonstrate efficient capital utilization, with a return on equity (ROE) of 17.44% and a return on assets (ROA) of 14.01%. The company generated a gross profit of $50.0 million on revenue of $64.0 million, implying a gross margin of approximately 78%. Operating income of $9.7 million and net income of $7.5 million reflect disciplined cost management and a clear path to the bottom line. These returns suggest a mature, cash-generative business model within the medical device niche.
Key takeaways
- Debt-free balance sheet with $15.3 million in cash provides strong financial flexibility.
- High profitability with 17.44% ROE and 14.01% ROA indicates efficient asset utilization.
- Strong operating cash flow of $11.4 million supports self-funded operations and potential dividends or buybacks.
- Low dilution and liquidity risks suggest a stable capital structure with no immediate financial distress signals.
- Strategic partnerships with major players like Philips and Baxter underscore the company's role in the HFCWO technology ecosystem.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$39,86
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$43.2M
Net cashⓘ
$15.3M
Current ratioⓘ
—
Debt / equityⓘ
—
ROAⓘ
14.0%
ROEⓘ
17.4%
Cash conversionⓘ
151.0%
CapEx / revenueⓘ
0.4%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships2 disclosed relationships · 1 type · extracted from filings & disclosures
Partners2
Baxter International IncBAX.OPartner95%Source ↗
Koninklijke Philips NVPHIA.ASPartner95%Source ↗
Supply chain
Vendors → ELMD ↔ Partners → Customers · click any node to drill
2 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution3 analysts
Strong buy0
Buy3
Hold0
Sell0
Strong sell0
12-month price target$40,33 · Median $40,00
Low $36,00High $45,00
Operating income · consensus13,5M USD
EPS surprise
−29,5 %
reported vs consensus · miss
Revenue surprise
−13,0 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$36,00
Mean$40,33
Median$40,00
High$45,00
Spot$39,86
+1.2 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin15,1 %Above P75
Net Margin11,8 %Above P75
ROE17,4 %Above P75
Capex / Rev0,4 %Above median
D/E0,00Above median
Cash Conv1,51Above median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net disposed 18 401 sh4 exercises · 2 grants3 insiders
- Director, CEO and President · Employee Stock Option (right to buy) → Common StockDisposed 9 700 @ $17,25exercise · 2026-06-08
- Chief Financial Officer · Employee Stock Option (right to buy) → Common StockDisposed 4 334 @ $10,25exercise · 2026-06-04
- Chief Financial Officer · Employee Stock Option (right to buy) → Common StockDisposed 5 267 @ $10,71exercise · 2026-06-04
- Director · Employee Stock Option (right to buy) → Common StockDisposed 40 000 @ $3,82exercise · 2026-05-15
- Director, CEO and President · Employee Stock Option (right to buy) → Common StockAcquired 31 100 @ $23,95grant · 2025-09-02
- Chief Financial Officer · Employee Stock Option (right to buy) → Common StockAcquired 9 800 @ $23,95grant · 2025-09-02
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Return On Equitynet_income / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Return On Assetsnet_income / total_assets
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
Source documents
- Electromed, Inc. Market data — financials · 2026-07-28
- reconciler_enqueue (reconciler) on ELMD.K · 2026-07-28
- Electromed Inc HA canonical relationships · 2026-07-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Brokerage Firms · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2025-12-310,00 %$13M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Leadership
- Jim L. CunniffPresident, Chief Executive Officer, Director
Insider activity
Net selling0 buys · 14 sellsnet -$3,8M9 insiders · last 365d
- Chief Financial Officer · Common StockOther 674 @ $42,30$29K · 2026-06-30
- Director, CEO and President · Common StockSold 1 026 @ $37,77$39K · 2026-06-08
- Director, CEO and President · Common StockSold 1 671 @ $36,80$61K · 2026-06-08
- Director, CEO and President · Common StockOther 9 700 @ $17,25$167K · 2026-06-08
- Director, CEO and President · Common StockSold 7 003 @ $36,25$254K · 2026-06-08
- Chief Financial Officer · Common StockOther 5 267 @ $10,71$56K · 2026-06-04
- Chief Financial Officer · Common StockSold 181 @ $37,11$7K · 2026-06-04
- Chief Financial Officer · Common StockOther 4 334 @ $10,25$44K · 2026-06-04
- Chief Financial Officer · Common StockSold 11 620 @ $36,34$422K · 2026-06-04
- Director · Common StockSold 19 032 @ $35,24$671K · 2026-05-15
- Director · Common StockSold 3 562 @ $37,33$133K · 2026-05-15
- Director · Common StockOther 40 000 @ $3,82$153K · 2026-05-15
- Director · Common StockSold 8 150 @ $34,36$280K · 2026-05-15
- Director · Common StockSold 9 256 @ $36,26$336K · 2026-05-15
- Director · Common StockOther 3 000 · 2025-12-01
- Director · Common StockOther 3 000 · 2025-12-01
- Director · Common StockOther 3 000 · 2025-12-01
- Director · Common StockOther 3 000 · 2025-12-01
- Director · Common StockOther 3 000 · 2025-12-01
- Director · Common StockOther 3 000 · 2025-12-01
- Director · Common StockOther 3 000 · 2025-12-01
- Director · Common StockSold 3 153 @ $24,42$77K · 2025-09-11
- Director · Common StockSold 404 @ $26,62$11K · 2025-09-10
- Director · Common StockSold 39 378 @ $23,68$932K · 2025-09-10
- Director · Common StockSold 16 203 @ $25,16$408K · 2025-09-10
Short positioning
194.5Kshares short+10.3% vs prior
1.24days to cover
40.8%short of daily vol
9fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
ELMD.KCanonical
NYSE · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companySectorPartners
Evidence & claims
From filings & derived data- Total liabilities (annual): USD 9.47MUnknown
- Total assets (annual): USD 54.91MUnknown
- Shareholders' equity (annual): USD 45.44MUnknown
- Current liabilities (annual): USD 9.38MUnknown
- Current assets (annual): USD 45.57MUnknown
- Shares outstanding (annual): 8.28MUnknown
- Cash & equivalents (annual): USD 13.79MUnknown
- Gross profit (annual): USD 49.97MUnknown
- Cost of revenue (annual): USD 14.03MUnknown
- Net income (annual): USD 7.54MUnknown
- Total operating expenses (annual): USD 40.31MUnknown
- EPS (diluted) (annual): USD-PER-SHARES 1Unknown
- R&D expense (annual): USD 996KUnknown
- EPS (basic) (annual): USD-PER-SHARES 1Unknown
- Capex (annual): USD 262KUnknown
- Operating income (annual): USD 9.66MUnknown
- Pre-tax income (annual): USD 10.28MUnknown
- Revenue (annual): USD 64MUnknown
- Operating cash flow (annual): USD 11.39MUnknown
- Total assets (annual): USD 52.27MUnknown
- Shares outstanding (annual): 8.56MUnknown
- Shareholders' equity (annual): USD 43.6MUnknown
- Cash & equivalents (annual): USD 16.23MUnknown
- Current assets (annual): USD 44.19MUnknown
Showing 24 of 36 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-08-09EVENTUpcomingFY 2026 earnings (expected) estimated date
2026-06-30INSIDERNagel Bradley M. transacted 674 sh — Chief Financial Officer ~$29k
2026-06-08 00:00 UTCINSIDER11 insider transactions — 2026-06 · net sell $515k 3 derivative
2026-06-08 00:00 UTCINSIDER11 insider transactions — 2026-06 · net sell $515k 3 derivative
2026-06-08INSIDERCunniff James L. sold 1.0k sh — Director, CEO and President ~$39k
2026-06-08INSIDERCunniff James L. sold 1.7k sh — Director, CEO and President ~$61k
2026-06-08INSIDERCunniff James L. transacted 9.7k sh — Director, CEO and President ~$167k
2026-06-08INSIDERCunniff James L. sold 7.0k sh — Director, CEO and President ~$254k
2026-06-08INSIDERCunniff James L. disposed of 9.7k sh Employee Stock Option (right to buy) — Director, CEO and President
2026-06-04INSIDERNagel Bradley M. transacted 5.3k sh — Chief Financial Officer ~$56k
2026-06-04INSIDERNagel Bradley M. sold 181 sh — Chief Financial Officer ~$7k
2026-06-04INSIDERNagel Bradley M. transacted 4.3k sh — Chief Financial Officer ~$44k
2026-06-04INSIDERNagel Bradley M. sold 11.6k sh — Chief Financial Officer ~$422k
2026-06-04INSIDERNagel Bradley M. disposed of 5.3k sh Employee Stock Option (right to buy) — Chief Financial Officer
2026-06-04INSIDERNagel Bradley M. disposed of 4.3k sh Employee Stock Option (right to buy) — Chief Financial Officer
2026-05-15 00:00 UTCINSIDER6 insider transactions — 2026-05 · net sell $1.3M 1 derivative
2026-05-15 00:00 UTCINSIDER6 insider transactions — 2026-05 · net sell $1.3M 1 derivative
2026-05-15INSIDERSKARVAN KATHLEEN sold 19.0k sh — Director ~$671k
2026-05-15INSIDERSKARVAN KATHLEEN sold 3.6k sh — Director ~$133k
2026-05-15INSIDERSKARVAN KATHLEEN transacted 40.0k sh — Director ~$153k
2026-05-15INSIDERSKARVAN KATHLEEN sold 8.2k sh — Director ~$280k
2026-05-15INSIDERSKARVAN KATHLEEN sold 9.3k sh — Director ~$336k
2026-05-15INSIDERSKARVAN KATHLEEN disposed of 40.0k sh Employee Stock Option (right to buy) — Director
2025-12-01 00:00 UTCINSIDER7 insider transactions — 2025-12
2025-12-01 00:00 UTCINSIDER7 insider transactions — 2025-12
2025-12-01INSIDERSKARVAN KATHLEEN transacted 3.0k sh — Director
2025-12-01INSIDERWalsh Andrea M. transacted 3.0k sh — Director
2025-12-01INSIDERTune Kathleen A transacted 3.0k sh — Director
2025-12-01INSIDERErickson Stan K. transacted 3.0k sh — Director
2025-12-01INSIDERFluet Gregory transacted 3.0k sh — Director
2025-12-01INSIDERGalatowitsch Joseph L. transacted 3.0k sh — Director
2025-12-01INSIDERSummers Andrew transacted 3.0k sh — Director
Showing the 40 most recent of 52 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage